THE EFFECTS OF LEUKOREDUCED BLOOD TRANSFUSION ON INFECTION RISK FOLLOWING INJURY: A RANDOMIZED CONTROLLED TRIAL

ABSTRACT Allogeneic blood transfusions in surgical patients have been associated with an increased risk of infectious complications and organ dysfunction. Residual leukocytes contaminating units of packed red blood cells have been incriminated through the induction of anergy and/or a potentiated inflammatory response, leading to the possibility that leukoreduced red blood cell transfusion might mitigate these effects. We set out to evaluate the effect of leukoreduced red cell transfusion on the risk of infections complications in patients requiring transfusion following injury. We conducted a single-center, double-blinded randomized controlled trial of leukoreduced versus standard, nonleukoreduced red blood cell transfusions in injured patients receiving transfusion within 24 hrs of injury. The primary endpoint was infectious complications within 28 days of randomization. Secondary end points were multiple organ failure, length of stay, febrile episodes, and mortality. Two hundred sixty eight subjects were eligible for analysis. Rates of infectious complications were similar in subjects receiving leukoreduced transfusions (30%) or standard transfusions (36%) ([RR], 0.84 [0.55-1.3]) and there was no statistically significant effect of leukoreduced blood transfusion on mortality [RR, 1.20 (0.74-1.9)], febrile episodes [RR, 1.01 (0.89-1.2)], or organ dysfunction scores (5.9 vs. 6.6; P = 0.29). Thus, pre-storage leukoreduction of allogeneic red blood cells had a small, but non-significant effect on the rate of infectious complication in this high-risk population requiring transfusion. There was no effect on the rates of febrile episodes, mortality, length of stay, or severity of organ dysfunction.

[1]  E. Vamvakas.  Is white blood cell reduction equivalent to antibody screening in preventing transmission of cytomegalovirus by transfusion? A review of the literature and meta-analysis. , 2005, Transfusion medicine reviews.

[2]  S. McLeskey,et al.  Predictors of Nosocomial Bloodstream Infections Among Critically Ill Adult Trauma Patients , 2004, Infection Control & Hospital Epidemiology.

[3]  R. Brand,et al.  Double-Blind, Randomized Controlled Trial on the Effect of Leukocyte-Depleted Erythrocyte Transfusions in Cardiac Valve Surgery , 2004, Circulation.

[4]  D. Fergusson,et al.  Transfusion of leukoreduced red blood cells may decrease postoperative infections: two meta-analyses of randomized controlled trials , 2004, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[5]  Edward L Snyder,et al.  Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction , 2004, Transfusion.

[6]  E. Vamvakas,et al.  WBC‐containing allogeneic blood transfusion and mortality: a meta‐analysis of randomized controlled trials , 2003, Transfusion.

[7]  H. Corwin,et al.  Is leukoreduction of blood components for everyone? , 2003, JAMA.

[8]  D. Coyle,et al.  Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. , 2003, JAMA.

[9]  E. Vamvakas.  Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting. , 2002, Transfusion medicine reviews.

[10]  G. Guyatt,et al.  Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis , 2002, BMJ : British Medical Journal.

[11]  J. Minei,et al.  Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. , 2002, The Journal of trauma.

[12]  J. Wallis,et al.  Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery , 2002, Transfusion.

[13]  S. Assmann,et al.  A prospective, randomized clinical trial of universal WBC reduction , 2002, Transfusion.

[14]  E. Vamvakas.  Possible mechanisms of allogeneic blood transfusion-associated postoperative infection. , 2002, Transfusion medicine reviews.

[15]  P. Coriat,et al.  The Effect of Universal Leukodepletion of Packed Red Blood Cells on Postoperative Infections in High-Risk Patients Undergoing Abdominal Aortic Surgery , 2002, Anesthesia and analgesia.

[16]  J. Sweeney,et al.  Universal leukoreduction of cellular blood components in 2001? Yes. , 2001, American journal of clinical pathology.

[17]  L. Goodnough,et al.  Universal leukoreduction of cellular blood components in 2001? No. , 2001, American journal of clinical pathology.

[18]  E. Moore,et al.  Blood transfusion and the two-insult model of post-injury multiple organ failure. , 2001, Shock.

[19]  S. Dzik,et al.  Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the-art conference. , 2001, Transfusion medicine reviews.

[20]  C. Graziano.  FDA 'not backing away' from universal leukoreduction. , 2000, CAP today.

[21]  J. Szalai,et al.  Infection in hospitalized trauma patients: incidence, risk factors, and complications. , 1999, The Journal of trauma.

[22]  P. Walsh,et al.  Randomized trial comparing packed red cell blood transfusion with and without leukocyte depletion for gastrointestinal surgery. , 1998, American journal of surgery.

[23]  J. Hermans,et al.  Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. , 1998, Circulation.

[24]  Y. Vanrenterghem,et al.  Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. , 1997, Transplantation.

[25]  C. Sprung,et al.  Multiple Organ Dysfunction Score , 1996 .

[26]  C. Sprung,et al.  Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. , 1995, Critical care medicine.

[27]  M. Blajchman,et al.  Immunosuppressive effects of allogeneic blood transfusions: implications for the patient with a malignancy. , 1995, Hematology/oncology clinics of North America.

[28]  T. Wobbes,et al.  Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer , 1994, The Lancet.

[29]  P. Christiansen,et al.  Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery , 1992, The British journal of surgery.

[30]  D A Rasley,et al.  Surveillance of nosocomial infections , 1989, Critical care nursing quarterly.

[31]  S. Baker,et al.  The injury severity score: an update. , 1976, The Journal of trauma.

[32]  W. Haddon,et al.  The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. , 1974, The Journal of trauma.

[33]  M. R. Mickey,et al.  Effect of blood transfusions on subsequent kidney transplants. , 1973, Transplantation proceedings.

[34]  D. Arteta,et al.  Early risk factors for sepsis in patients with severe blunt trauma. , 2001, Injury.

[35]  E. Moore,et al.  Stored red blood cells selectively activate human neutrophils to release IL-8 and secretory PLA2. , 2000, Shock.

[36]  Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. , 1997, The New England journal of medicine.